**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

---

### 1. Name and Address of Reporting Person
Stewart Jeffrey Ryan

1 NORTH WAUKEGAN ROAD
NORTH CHICAGO IL 60064

### 2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

### 3. Date of Earliest Transaction (Month/Day/Year)
03/24/2022

### 5. Relationship of Reporting Person(s) to Issuer

- **Director**
- **10% Owner**
- **EVP, Chief Commercial Officer**

### 4. If Amendment, Date of Original Filed (Month/Day/Year)
03/24/2022

### 6. Individual or Joint/Group Filing (Check Applicable Line)

- **X** Form filed by One Reporting Person
- **X** Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>03/24/2022</td>
<td></td>
<td>M</td>
<td>27,690 A</td>
<td>88,631</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
<td>03/24/2022</td>
<td></td>
<td>S</td>
<td>27,690 D</td>
<td>60,941</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock, $0.01 par value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>By spouse in trust</td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>4. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Option (Right to Buy)</td>
<td>$58.88</td>
<td>03/24/2022</td>
<td>M</td>
<td>27,690</td>
<td>02/19/2016</td>
<td>Common Stock 27,690 $58.88</td>
<td>Common Stock</td>
<td>02/18/2025</td>
<td>D</td>
<td></td>
</tr>
</tbody>
</table>

---

**Explanation of Responses:**

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.86 to $159.55 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The reporting person disclaims beneficial ownership of all securities held by his spouse.

3. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

**Remarks:**

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

---

**Steven L. Scrogham, attorney-in-fact for Jeffrey R. Stewart**

03/25/2022

**Signature of Reporting Person**

Date

---

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.